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healthy subjects (26). Because the adverse effects of homo-
cysteine are most likely related to its prooxidant proper-
ties (6 ), a direct involvement of the amino acid in this
phenomenon may be therefore hypothesized.
In conclusion, PD patients undergoing regular treat-
ment with l-DOPA have higher plasma homocysteine
concentrations than healthy subjects. The increase seems
to be related to the methylated catabolism of the drug,
although other factors, such as enzymatic defects in the
remethylation pathway of homocysteine, are likely to
play a substantial role. Increased risk of cerebro- and
cardiovascular diseases has been reported in PD patient
populations, although the issue is highly disputed
(27, 28). Whether the increase in plasma homocysteine
occurring in PD patients plays a role in the progression of
the disease remains to be established.
This study was supported by a grant of the Ministry of
Health of the Italian Government to the Neurological
Institute C. Mondino (Ricerca Corrente 1998).
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Enzymes of the cytochrome P450 system are involved in
the metabolism of a broad range of foreign compounds,
such as drugs, environmental pollutants, and carcinogens
(1 ). The most abundant enzyme in the human liver is
cytochrome P450 3A4 (CYP3A4) (2 ). This enzyme is
involved in the metabolism of .50% of all drugs used in
humans (3, 4), and the interindividual differences in the
pharmacokinetics of these drugs are thought to be related
to variations in CYP3A4 activity (4–6). These variations
may be caused by age and disease-related differences, by
drugs inducing or repressing transcription/translation, or
by genetic polymorphisms. Although the CYP3A4 gene
was initially thought not to be polymorphic, recent re-
ports have described three genetic variants of this gene:
CYP3A4*1B, CYP3A4*2, and CYP3A4*3 (7, 8). The allelic
frequency for the CYP3A4*1B allele, which contains
an A(2290)G substitution in the promoter region of
CYP3A4, ranges from 0.0% in Chinese and Japanese
Americans to .54% in African Americans (8, 9). Ameri-
can and European Caucasians were reported to have an
allelic frequency of ;4–5% (8–11). The CYP3A4*2 allele,
which encodes a Ser222Pro change, has an allelic fre-
quency of 2.7% in the white (Finnish) population (8 ).
Because variant alleles that are found in .1% of the
population are defined as genetic polymorphisms (12 ),
both the CYP3A4*1B and the CYP3A4*2 allele are consid-
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ered to be genetic polymorphisms of CYP3A4. In addition,
a variant allele found in the DNA of a single Chinese
subject contained a T1437C substitution (8 ). Because this
allele, encoding a Met445Thr change, was not found in
any other of the 91 subjects investigated in that study, it
was referred to as a rare allele.
In this study, we developed a PCR-restriction fragment
length polymorphism (RFLP) procedure for the detection
of the CYP3A4*3 allele. We used this assay to determine
the allelic frequency of CYP3A4*3. EDTA-whole blood
was obtained from 499 healthy Dutch Caucasian volun-
teers after informed consent. The study was approved by
the Medical Ethical Committee of the University Hospital
Rotterdam. We isolated genomic DNA from 300 mL of
blood, using the GenomicPrep Blood DNA Isolation re-
agent set (Amersham Pharmacia Biotech). DNA yields
were estimated by measuring the absorbance at 260 nm
(A260). A total of ;50 ng of genomic DNA was used in a
PCR volume of 50 mL. The PCR mixture contained 13
buffer [10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2, 50 mM
KCl, and 0.01 g/L gelatin (Perkin-Elmer)], 0.2 mM each
dNTP (Roche), 1.25 U of AmpliTaq Gold (Perkin-Elmer),
and 40 pmol of each of forward primer (59-TGG ACC
CAG AAA CTG CAT ATG C-39; nucleotides 23255–23276;
GenBank sequence AF209389) and reverse primer (59-
GAT CAC AGA TGG GCC TAA TTG-39; nucleotides
23483–23503; GenBank sequence AF209389). The nucleo-
tides underlined are mismatches with the CYP3A4 se-
quence, creating a NsiI restriction site in the wild-type
CYP3A4 PCR product. When the CYP3A4*3 allele is
amplified, this NsiI site is disrupted. PCR conditions were
as follows: 7 min at 94 °C; 35 cycles of 1 min at 94 °C, 1
min at 55 °C, and 1 min at 72 °C; and finally 7 min at
72 °C. The 249-bp PCR products of five DNA samples
were sequenced, confirming that indeed only the CYP3A4
gene was amplified.
The PCR product (15 mL) was digested with 10 U of NsiI
(Roche) for 2 h at 37 °C, and analyzed on a 3% MP
agarose/Tris-borate-EDTA gel with ethidium bromide
staining. The fragments produced were 226 and 23 bp for
the wild-type sequence (Fig. 1, lane wt/wt) and 249, 226,
and 23 bp for heterozygous sequences (Fig. 1, lane wt/*3);
the 23-bp fragments are not visible on the gel. Samples
that produced a heterozygous signal were reanalyzed
using the PCR-RFLP assay. Subsequently, heterozygosity
for CYP3A4*3 was confirmed by sequencing of the PCR
product with the reverse primer on an automated ABI 310
capillary sequencer (Perkin-Elmer) using the Big Dye
Terminator Cycle Sequencing reagent set (Perkin-Elmer).
To check reproducibility, the CYP3A4*3 assay was per-
formed 10 times for a wild-type and 10 times for a
heterozygous sample; the genotype was identified cor-
rectly each time.
The CYP3A4*3 PCR-RFLP assay was applied to 499
genomic DNA samples obtained from Dutch Caucasians.
In 488 cases, digestion of the 249-bp PCR product pro-
duced the 226- and 23-bp fragments, as expected for
wild-type samples, whereas in 11 cases (2.2%), the het-
erozygous signal was produced. No homozygotes were
detected. The allelic frequency of CYP3A4*3 in these
Caucasians was therefore 1.1%. These allelic and geno-
typic frequencies are in Hardy-Weinberg equilibrium
(P 5 0.80). In the heterozygous samples, direct sequencing
showed a mixed T/C peak corresponding to position
1437, indicating that the nucleotide change was indeed
T1437C in all cases.
Variant CYP3A4 alleles in the population may contrib-
ute to interindividual variability in CYP3A4 activity, and
detecting genetic polymorphisms may help to predict an
individual’s ability to respond to certain drugs. The
CYP3A4*3 allele, which has a T1473C change that pro-
duces a Met445Thr substitution in exon 12, was found in
only 1 Chinese subject from Shanghai and could not be
detected in 91 other individuals (8 ). Because of this,
CYP3A4*3 was described as being a rare allele, which may
lead researchers to assign a low priority to performing
functional studies on this allele. Our data indicate that the
CYP3A4*3 allele is not limited to a single individual, but
has an allelic frequency of 1.1% in Caucasians. This
implies that the variant CYP3A4*3 allele is not a rare
allele, but instead represents a genetic polymorphism that
can be found in a substantial part of the population. The
identification of the CYP3A4*3 variant allele as a genetic
polymorphism, in addition to the CYP3A4*1B and *2
polymorphisms, has implications for the number of vari-
ant CYP3A4 alleles to be expected in the population. The
CYP3A4*1B allele potentially alters the transcription effi-
ciency and thus the overall enzymatic activity of CYP3A4.
Although initial reports suggested decreased activity in
vivo (7, 13, 14), increased activity in vitro (15, 16) and no
effect (10, 14, 17) have also been reported. For the variant
allele CYP3A4*2, a decreased enzymatic activity was
observed for nifedipine, but not for testosterone (8 ). For
CYP3A4*3, the location of the amino acid that is changed
in the CYP3A4 protein is near the cysteine that is involved
in the active site of the enzyme (8 ). This might induce
structural differences, leading to alteration in enzymatic
Fig. 1. PCR-RFLP procedure for the CYP3A4*3 allele.
Analysis on a 3% agarose/Tris-borate-EDTA gel. Lane 0, undigested PCR product;
lane wt/wt, NsiI-digested PCR fragments of 226 and 23 bp for a wild-type DNA
sample; lane wt/*3, NsiI-digested PCR fragments of 249, 226, and 23 bp for a
heterozygous DNA sample. The 23-bp fragment is not visible. Lanes M, base pair
marker (50-bp ladder). Gel is printed as a negative.
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activity. However, expression studies need to be per-
formed to confirm this. Taking into account the allelic
frequencies of the genetic polymorphisms in CYP3A4
(10% heterozygous for CYP3A4*1B, 5.4% heterozygous for
CYP3A4*2, and 2.2% heterozygous for CYP3A4*3), this
implies that ;15% of the (Caucasian) population may
carry a genetic polymorphism in this allele. Because
genetic polymorphisms may exhibit strong differences in
occurrence among different ethnic groups, other popula-
tions need to be investigated to determine the allelic
frequency of CYP3A4*3.
In conclusion, we have described and validated a
PCR-RFLP assay for the CYP3A4*3 allele. The frequency
of this variant allele in the Caucasian population (1.1%)
indicates that it might be important in predicting CYP3A4
activity based on genotype. Future research should be
directed toward elucidating the effect of this polymor-
phism on CYP3A4 enzymatic activity and toward estab-
lishing whether this is solely a genetic, or also a func-
tional, polymorphism.
We thank the Bloodbank ZWN Rotterdam for their coop-
eration in collecting blood samples. We also thank Dr. Y.
Fang for technical assistance.
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NO is produced in many different cells and is involved in
the regulation of such physiological and pathophysiolog-
ical processes as inflammation, vasodilation, and metab-
olism (1 ). Depending on the cell type, NO is produced in
an enzymatic reaction catalyzed by one of the three
isoforms of NO synthase (NOS): neuronal NOS, endothe-
lial NOS, and inducible NOS (2 ). Measurement of the NO
metabolites, nitrate and nitrite (NOx), is also important as
a marker of NOS enzyme activity.
Obesity is a condition involving an excess accumulation
of body fat, and the prevalence of obesity is rapidly
increasing worldwide. Excessive weight and obesity are
leading to nutrition-related disorders of clinical and pub-
lic health concern. Recent studies have suggested a role
for NO in the regulation of food intake in an animal
experiment (3, 4). Endothelial and inducible NOS have
been shown to be present in adipose tissue of the rat (5 ),
suggesting that adipose tissue may be a potential source
of NO production. Previous reports demonstrated that
NOS activity and inducible NOS protein were also
present in human subcutaneous adipose tissue (6 ) and
showed that inhibition of NOS led to increased lipolysis
in this tissue (7 ). However, how NO production changes
as body mass index (BMI) increases in apparently healthy
subjects has not been studied extensively. Moreover,
correlation studies of serum NOx concentrations, body fat
mass, and blood lipid concentrations in healthy subjects
are limited. Therefore, in the present study, we investi-
gated the changes in NOx concentrations according to
BMI and evaluated the relationships among NOx concen-
trations, total body fat, and lipid profiles in adolescents.
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